Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses Polymorphism Patent from Vanderbilt

NEW YORK, Jan. 26 (GenomeWeb News) - Genaissance Pharmaceuticals has exclusively licensed commercial rights to a patent held by Vanderbilt University that it said would expand its ability to provide genetic tests for variants of cardiac ion-channel proteins involved in drug-induced cardiac arrhythmias.


Genaissance gained rights to US Patent No. 6,458,542, which covers the screening of patients for susceptibility of drug-induced cardiac arrhythmias by testing for the presence of a common polymorphism in KCNE1, a cardiac ion channel gene. The patent adds to Genaissance's estate of more than 50 issued and pending patents covering five cardiac ion-channel genes associated with Long QT Syndrome.


New Haven, Conn.-based Genaissance developed the Familion Test for cardiac channelopathies, including Long QT Syndrome and Brugada Syndrome.


Terms of the license were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.